Department of Clinical Laboratory, the Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Sci Rep. 2017 Oct 12;7(1):13080. doi: 10.1038/s41598-017-10001-0.
The present meta-analysis aimed to analyze available data to identify the prognostic role of NEAT1 in multiple carcinomas. A systematic search was performed by using several computerized databases from inception to June 7, 2017. The quantity of the publications was assessed according to MOOSE checklist. Pooled HRs with 95% CI was calculated to summarize the effect. A total of 12 studies with 3,262 cancer patients were pooled in the analysis to evaluate the prognostic value of NEAT1 in multiple tumors. High expression levels of NEAT1 were demonstrated to be associated with poor OS (HR = 1.71, 95%CI: 1.37-2.14, P < 0.001) and tumor progression (III/IV vs. I/II: HR 1.76, 95%CI: 1.40-2.21, P < 0.00001). Subgroup analysis showed that NEAT1 detection method (qRT-PCR) and sample size (more or less than 100) did not alter the predictive value of NEAT1 on OS in various cancers. According to the meta-regression results, the large heterogeneity of meta-analysis may be attributed to the differences of NEAT1 detection method. Furthermore, elevated NEAT1 expression significantly predicted lymph node metastasis (HR: 2.10, 95%CI: 1.32-3.33, P = 0.002) and distant metastasis (HR: 2.80, 95%CI: 1.60-4.91, P = 0.0003) respectively. The results indicate that NEAT1 expression level is a prognostic biomarker for OS and metastasis in general tumors.
本荟萃分析旨在分析现有数据，以确定 NEAT1 在多种癌症中的预后作用。从成立到 2017 年 6 月 7 日，使用几个计算机数据库进行了系统搜索。根据 MOOSE 清单评估出版物的数量。汇总了 HRs 及其 95%CI，以总结效果。共有 12 项研究共 3262 例癌症患者纳入分析，以评估 NEAT1 在多种肿瘤中的预后价值。结果表明，NEAT1 高表达与总生存期（OS）不良（HR=1.71，95%CI：1.37-2.14，P<0.001）和肿瘤进展（III/IV 期比 I/II 期：HR 1.76，95%CI：1.40-2.21，P<0.00001）相关。亚组分析表明，NEAT1 检测方法（qRT-PCR）和样本量（大于或小于 100）不会改变 NEAT1 在各种癌症中对 OS 的预测价值。根据荟萃回归结果，荟萃分析的大量异质性可能归因于 NEAT1 检测方法的差异。此外，升高的 NEAT1 表达显著预测了淋巴结转移（HR：2.10，95%CI：1.32-3.33，P=0.002）和远处转移（HR：2.80，95%CI：1.60-4.91，P=0.0003）。结果表明，NEAT1 表达水平是一般肿瘤 OS 和转移的预后生物标志物。
